HOME >> BIOLOGY >> NEWS
JCI table of contents, 2 June, 2003

Turning foe into friend with lentiviral vectors

Currently, there is no vaccine available that is able to cure cancer. The success of an antitumor vaccine will depend on its ability to induce robust and sustained tumor-specific immune responses. There is evidence to suggest that antitumor vaccination can induce such responses and even tumor regression. However, to date these regressions have not been long-lasting. Researchers at the Ludwig Institute for Cancer Research in Switzerland have developed a lentiviral vaccine which following injection into mice is capable of inducing an antigen-specific T cell response. This approach represents an attractive candidate for cancer therapy.

The crucial stimulation of a T cell response is dependent on the presentation of the antigen by host dendritic cells (DCs). As part of earlier strategies, the antigen of interest has been transferred to host DCs (by a process called transduction) outside the body and the DCs then reintroduced into the host. Unfortunately, this is a costly and labor-intensive process.

In the June 2 issue of the Journal of Clinical Investigation, Christopher Esslinger and colleagues describe their use of a third generation lentivector capable of transducing DCs in vivo in mice and inducing a very strong antigen-specific immune response. The immune response was shown to be superior to methods using DCs transduced outside the body in terms of both amplitude and persistence.

Our results demonstrate that the time-consuming and costly steps currently used to elicit tumor-specific cytotoxic T lymphocyte responses through the transfer of ex-vivo manipulated DCs could be replaced by the much simpler direct in vivo administration of antigen recombinant lentivectors states Dr. Esslinger.

TITLE: In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses

AUTHOR CONTACT:
Christoph Esslinger
Ludwig Institute for
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
2-Jun-2003


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents September 15, 2004
4. JCI table of contents: 1 September, 2004
5. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
6. JCI table of contents, 16 August, 2004
7. JCI table of contents, 2 August, 2004
8. When male fish hum, females swim in, thanks to hormones, adaptable hearing
9. JCI table of contents, 1 July 2004
10. Search and destroy protein turns tables on HIV
11. JCI table of contents, 15 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: